Indexado en

Licencia y uso

Citaciones

Cited 7 times in

Altmetrics

Análisis de autorías institucional

Compartir

Clinical features and outcomes in carriers of pathogenic desmoplakin variants.

Publicado en:European heart journal. 46 (4): 362-376 - 2025-01-21 46(4), DOI: 10.1093/eurheartj/ehae571

Autores: Gasperetti A; Carrick RT; Protonotarios A; Murray B; Laredo M; van der Schaaf I; Lekanne RH; Syrris P; Cannie D; Tichnell C; Cappelletto C; Gigli M; Medo K; Saguner AM; Duru F; Gilotra NA; Zimmerman S; Hylind R; Abrams DJ; Lakdawala NK; Cadrin-Tourigny J; Targetti M; Olivotto I; Graziosi M; Cox M; Biagini E; Charron P; Casella M; Tondo C; Yazdani M; Ware JS; Prasad SK; Calò L; Smith ED; Helms AS; Hespe S; Ingles J; Tandri H; Ader F; Peretto G; Peters S; Horton A; Yao J; Dittmann S; Schulze-Bahr E; Qureshi M; Young K; Carruth ED; Haggerty C; Parikh VN; Taylor M; Mestroni L; Wilde A; Sinagra G; Merlo M; Gandjbakhch E; van Tintelen JP; Te Riele ASJM; Elliott PM; Calkins H; James CA

Afiliaciones

Resumen

Pathogenic variants in the desmoplakin (DSP) gene are associated with the development of a distinct arrhythmogenic cardiomyopathy phenotype not fully captured by either dilated cardiomyopathy (DCM), non-dilated left ventricular cardiomyopathy (NDLVC), or arrhythmogenic right ventricular cardiomyopathy (ARVC). Prior studies have described baseline DSP cardiomyopathy genetic, inflammatory, and structural characteristics. However, cohort sizes have limited full clinical characterization and identification of clinical and demographic predictors of sustained ventricular arrhythmias (VAs), heart failure (HF) hospitalizations, and transplant/death. In particular, the relevance of acute myocarditis-like episodes for subsequent disease course is largely unknown. All patients with pathogenic/likely pathogenic (P/LP) DSP variants in the worldwide DSP-ERADOS Network (26 academic institutions across nine countries) were included. The primary outcomes were the development of sustained VA and HF hospitalizations during follow-up. Fine-Gray regressions were used to test association between clinical and instrumental parameters and the development of outcomes. Eight hundred patients [40.3 ± 17.5 years, 47.5% probands, left ventricular ejection fraction (LVEF) 49.5 ± 13.9%] were included. Over 3.7 [1.4-7.1] years, 139 (17.4%, 3.9%/year) and 72 (9.0%, 1.8%/year) patients experienced sustained VA and HF episodes, respectively. A total of 32.5% of individuals did not fulfil diagnostic criteria for ARVC, DCM, or NDLVC; their VA incidence was 0.5%/year. In multivariable regression, risk features associated with the development of VA were female sex [adjusted hazard ratio (aHR) 1.547; P = .025], prior non-sustained ventricular tachycardia (aHR 1.721; P = .009), prior sustained VA (aHR 1.923; P = .006), and LVEF ≤ 50% (aHR: 1.645; P = .032), while for HF, they were the presence of T-wave inversion in 3+ electrocardiogram leads (aHR 2.036, P = .007) and LVEF ≤ 50% (aHR 3.879; P < .001). Additionally, 70 (8.8%) patients experienced a myocardial injury episode at presentation or during follow-up. These episodes were associated with an increased risk of VA and HF thereafter (HR 2.394; P < .001, and HR 5.064, P < .001, respectively). Patients with P/LP DSP variants experience high rates of sustained VA and HF hospitalizations. These patients demonstrate a distinct clinical phenotype (DSP cardiomyopathy), whose most prominent risk features associated with adverse clinical outcomes are the presence of prior non-sustained ventricular tachycardia or sustained VA, T-wave inversion in 3+ leads on electrocardiogram, LVEF ≤ 50%, and myocardial injury events.

Palabras clave